The Munich-based health tech startup Meliodays Medical raised €800,000 in a pre-seed financing round. The round was significantly oversubscribed and was led by Capacura, with participation from FS Life Science Investment and other early-stage investors and business angels specializing in the healthcare market. Simone Sabbione, co-founder and CEO of Meliodays Medical, is delighted:
"We are delighted to have attracted such experienced healthcare and impact investors for our initial financing and warmly welcome them to Meliodays' shareholder base. Their investment and the strong interest in our significantly oversubscribed pre-seed round demonstrate that period pain is now recognized as a serious health concern for large segments of the global population. Now we can finally work on urgently needed solutions."
Alternative to conventional treatment methods
With this financing round, Meliodays Medical to advance the development of MelioOne, a novel hormone-free, locally acting therapy for the treatment of menstrual pain. The therapy is intended to offer an innovative alternative to current treatment options such as hormone therapies and pain medications, which are often associated with undesirable systemic side effects.
The fresh capital will be used specifically to complete preclinical testing of MelioOne's innovative intrauterine application. The treatment uses a proven polymer technology to release a small amount of painkillers directly into the uterus. This enables targeted relief of period pain without systemic side effects. In the future, the technology could also be used to treat endometriosis, another condition associated with painful symptoms.
Patented in over 150 countries
The Munich-based startup has already secured the patent rights for MelioOne in over 150 countries worldwide. With this broad international coverage, the company plans to scale its innovative technology globally and offer menstruating people a new, effective, and low-risk treatment option.
